Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Pharmaceuticals

ScinoPharm To Supply Obesity Drug Active

by Jean-François Tremblay
July 30, 2012 | A version of this story appeared in Volume 90, Issue 31

Taiwan’s ScinoPharm will supply the drug company Vivus with a key active pharmaceutical ingredient for the obesity drug Qsymia. Approved by FDA earlier this month, Qsymia combines the anticonvulsant topiramate, which ScinoPharm will supply, and the appetite suppressant phentermine. ScinoPharm says it started supplying topiramate to Vivus during Qsymia’s clinical development. The Taiwanese firm first made generic topiramate, which is also used to treat epilepsy and nervous system disorders, two years ago.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.